Clinical Trials Directory

Trials / Conditions / Coronavirus Disease (COVID-19)

Coronavirus Disease (COVID-19)

26 registered clinical trials studyying Coronavirus Disease (COVID-19) — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People
NCT06667700
Merck Sharp & Dohme LLCPhase 3
WithdrawnSurvey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms
NCT04892888
Takeda—
CompletedA Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
NCT05299359
TakedaPhase 3
CompletedSafety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribon
NCT05119855
Merck Sharp & Dohme LLCPhase 3
CompletedLong-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
NCT04941144
ModernaTX, Inc.—
CompletedStudy of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
NCT04939428
Merck Sharp & Dohme LLCPhase 3
UnknownTo Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
NCT04885361
OSE ImmunotherapeuticsPhase 1
CompletedA Study of TAK-919 in Healthy Japanese Adults (COVID-19)
NCT04677660
TakedaPhase 1 / Phase 2
TerminatedDose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
NCT04569786
Merck Sharp & Dohme LLCPhase 1
TerminatedEfficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
NCT04575584
Merck Sharp & Dohme LLCPhase 2 / Phase 3
CompletedEfficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-00
NCT04575597
Merck Sharp & Dohme LLCPhase 2 / Phase 3
CompletedImmuneSense™ COVID-19 Study
NCT04583982
Adaptive Biotechnologies—
CompletedAerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019
NCT04609774
Hospital Italiano de Buenos Aires—
UnknownCardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19)
NCT04572360
Hong Kong Baptist UniversityN/A
TerminatedA Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants
NCT04498247
Merck Sharp & Dohme LLCPhase 1 / Phase 2
UnknownD-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia
NCT04584580
Ain Shams UniversityPhase 4
UnknownAin Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients
NCT04584606
Ain Shams University—
CompletedFeasibility of Rapid COVID-19 Testing in Disadvantaged Populations
NCT04558307
Mayo Clinic—
UnknownLevamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
NCT04360122
Ain Shams UniversityPhase 3
CompletedScreening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hosp
NCT04348214
Ain Shams University—
UnknownPlasma Rich Antibodies From Recovered Patients From COVID19
NCT04348877
Ain Shams UniversityN/A
UnknownApplication of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COV
NCT04350931
Ain Shams UniversityPhase 3
UnknownTo Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database
NCT04346043
Ain Shams University—
CompletedEfficacy and Safety of Favipiravir in Management of COVID-19
NCT04349241
Ain Shams UniversityPhase 3
UnknownRetrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19
NCT04346056
Ain Shams University—
WithdrawnFingolimod in COVID-19
NCT04280588
First Affiliated Hospital of Fujian Medical UniversityPhase 2